Page 20 - Diffusion Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gainers VistaGen Therapeutics (NASDAQ:VTGN) stock rose 22.6% to $2.82 during Wednesday’s after-market session. This security traded at a volume of 1.3 million shares come close, making up 46.76% of its average volume over the last 100 days. The company’s market cap stands at $536.3 million. PolarityTE (NASDAQ:PTE) stock rose 9.27% to $1.07. At the close, PolarityTE’s trading volume reached 478.5K shares. This is 9.86% of its average volume over the last 100 days. The market value of their outstanding shares is at $86.2 million. The company’s, Q1 earnings came out 4 days ago. Frequen...

Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively. Discoveries of isocitrate dehydrogenase (IDH) mutation, co-deletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p19q), O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation, and histone H3-K27M mutation have led to a better understanding of the molecular aberrations associated with Brain Tumors. Pondering over changing dynamics of the Brain Tumor market? Request a Sample for more @ A Brain Tumor, also known as an intracranial tumor, or ce...

(1) LAS VEGAS, March 4, 2021 /PRNewswire/ -- Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100?000 per year. However, these cases are not confined to one or the other particular geography, but are disproportionately spread across the world. Many rare human cancers are not curable, and have limited number of treatment options. Rare cancers are more difficult to diagnose and are often misdiagnosed. Rarity of the cancers further complicates the running of cli...

Gainers ClearPoint Neuro (NASDAQ:CLPT) stock rose 8.48% to $27.99 during Thursday's after-market session. This security traded at a volume of 10.5K ...

(1) BASEL (dpa-AFX) - Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio's regulatory catalyst for this year, partial hold on Cortexyme's open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer's disease, and expanded FDA approval of Novartis' Entresto. Read on. 1. Sickle Cell Disease Trial Blues For bluebird bio Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company's LentiGlobin gene therapy trials for sickle cell disease were temporarily suspen...